In the present phase medicinal biotechnology for development of modern diagnosis methods using PCR, RT-PCR as well as genomic and proteomic analysis for emerging infectious diseases such as HPAI (Highly Pathogenic Avian Influenza), SARS (Severe Acute Respiratory Syndrome) and genomic diseases are put into the objectives of R&D. Recombinant sub-unit proteins have been produced and utilized as agents in diagnostic immunological kits for dengue fever virus, for veterinary and plant pathogenic viruses and also as preventive vaccines for hepatitis B. Characterization of mitochondrial genomic specificities and identities for ethnic groups will also contribute to understanding their epidemiologic and phylogenic characteristics. The analysis of SNP in genomes of patients and their progenies who have been exposed to chemical war agents will explain the long lasting effects of these toxic compounds on the human genome and its impacts to inherited diseases. DNA gene chips are also belonging to the prioritized field of interests.